NasdaqGS:ADPTLife Sciences
Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?
Investor sentiment shift after earnings-focused rating upgrade
Adaptive Biotechnologies (ADPT) is back on investors’ radar after a recent upgrade to a Zacks Rank #2 (Buy). The move is tied to higher earnings estimates and a more constructive view on its earnings outlook.
See our latest analysis for Adaptive Biotechnologies.
The recent Zacks upgrade comes as Adaptive Biotechnologies’ share price has rallied, with a 28.81% 1 month share price return and 59.01% 3 month share price return. Its 1...